Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3703784 | 0.87 | NEK2 (0.31) | NEK2 | |
| SCHEMBL337666 | 0.83 | — | — | |
| SCHEMBL102823 | 0.82 | — | — | |
| SCHEMBL4574477 | 0.82 | — | — | |
| SCHEMBL482290 | 0.80 | — | — | |
| SCHEMBL21591256 | 0.76 | — | — | |
| SCHEMBL15264796 | 0.76 | — | — | |
| SCHEMBL380825 | 0.74 | — | — | |
| SCHEMBL19856433 | 0.74 | — | — | |
| SCHEMBL2504563 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 781 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024140637-A1 | OXOISOINDOLINYL SUBSTITUTED PIPERIDINEDIONE DERIVATIVE AND USE THEREOF | 标新生物医药科技(上海)有限公司 | 2024-07-04 | — | — | WO | claimed |
| EP-4392415-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | Yuhan Corporation (KR) | 2024-07-03 | — | — | EP | claimed |
| US-20240199581-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | claimed |
| US-12012410-B2 | Substituted pyrazolo[1,5-a]pyrazines for spinal muscular atrophy | REBORNA BIOSCIENCES, INC. (JP) | 2024-06-18 | — | — | US | claimed |
| EP-3468953-B1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-05-22 | — | — | EP | claimed |
| US-11981658-B2 | Substituted aminopyridine compounds as EGFR inhibitors | YUHAN CORPORATION (KR) | 2024-05-14 | — | — | US | claimed |
| EP-4351583-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | claimed |
| EP-4295910-A2 | METHODS FOR TREATING MULTIPLE SCLEROSIS USING PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY | Merck Patent GmbH (DE) | 2023-12-27 | — | — | EP | claimed |
| WO-2023225244-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | BIOGEN MA INC. (US) | 2023-11-23 | — | — | WO | claimed |
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2023-10-19 | — | — | US | claimed |
| US-20120276121-A1 | USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES | INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) | 2012-11-01 | — | — | US | claimed |
| EP-2215085-B1 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-09-07 | — | — | EP | claimed |
| EP-2318363-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | Nuevolution A/S (DK) | 2011-05-11 | — | — | EP | claimed |
| EP-2215085-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-11 | — | — | EP | claimed |
| US-20090324580-A1 | Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases | CENIX BIOSCIENCE GMBH (DE) | 2009-12-31 | — | — | US | claimed |
| WO-2009152824-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2009-12-23 | — | — | WO | claimed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | claimed |
| WO-2009053737-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | claimed |
| EP-1991215-A1 | USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES | Cenix Bioscience GmbH (DE) | 2008-11-19 | — | — | EP | claimed |
| WO-2007101710-A1 | USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES | CENIX BIOSCIENCE GMBH (DE) | 2007-09-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012410-B2 | Substituted pyrazolo[1,5-a]pyrazines for spinal muscular atrophy | SMN1; SMN2, HDAC5, PUM1 | NEK2 2333/4885OPRM1 3545/4885 |
| US-20240199581-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | BRAF, NRAS, KRAS | NEK2 848/4885OPRM1 4480/4885 |
| US-20090324580-A1 | Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases | SCARB1, MSR1, HAVCR2 | NEK2 4270/4885OPRM1 3385/4885 |
| US-20120276121-A1 | USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES | SCARB1, MSR1, HAVCR2 | NEK2 4270/4885OPRM1 3385/4885 |
| US-20230331725-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, HDAC6 | NEK2 944/4885OPRM1 3763/4885 |
| US-11981658-B2 | Substituted aminopyridine compounds as EGFR inhibitors | EGFR, ERBB2, ERBB4 | NEK2 490/4885OPRM1 833/4885 |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | MKI67, CCND3, CCND1 | NEK2 348/4885OPRM1 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.